Related Experiment Videos
[Association of atherosclerosis and cardiac cell dysfunction]
H Yonemochi1, M Nakagawa, T Iwao
1Department of Laboratory Medicine, Medical University of Oita.
Insights
Angiotensin-converting enzyme inhibitors (ACEi) enhance cardiac function by increasing beta-receptors in heart cells. This effect, mediated by bradykinin, may help treat heart failure and atherosclerosis.
Area of Science:
- Cardiology
- Pharmacology
- Cellular Biology
Abstract:
It is recognized that heart failure in patients with atherosclerotic lesion is the result of ischemia. However, there may also be cardiac cell dysfunction independent of ischemia, as factors advancing both of atherosclerosis and heart failure are discovered. The renin-angiotensin system is one of factor and angiotensin-converting enzyme inhibitor (ACEi) prevents progression of atherosclerotic lesion and heart failure. To elucidate the association of atherosclerosis and cardiac cell dysfunction, we investigated the effects of ACEi on cultured cardiac myocytes. Captopril increased beta-receptor density of myocytes and augmented the response to isoproterenol. CV-3480, a ACEi, also up-regulated beta-receptors but angiotensin I, angiotensin II and angiotensin type I receptor antagonist did not. Bradykinin B2 receptor blocker, HOE140, suppressed the effect of captopril on cultured cells. The results suggest that ACEi up-regulated beta-receptors and augmented the response to beta-receptor agonist through BK potentiation.